Investors

Why invest

Our vision is to make MOB-015, launched in Sweden and Norway under the brand name Terclara®, the leading nail fungus treatment globally, and to build a specialty pharmaceutical company with our own sales in the U.S. and sales through partners in other markets.

World-leading anti-fungal effect

76% of the patients became fungus-free in two phase 3 studies that included over 800 patients
MOB-015 is a topical formulation of terbinafine. 1000 times lower concentration of terbinafine in the blood compared to oral treatment.
Strong premium position from true competitive advantage: Targeting category leadership with USD 250-500m potential global product sales

Strong commercial partners in place

Europa, APAC, China
Scandinavia
Canada
Israel

Market leader in nail fungus

Terclara^® became the market leader in Sweden and Norway instantly after starting consumer marketing
National marketing authorization approvals received in 14 countries, whereof 8 granted OTC status. The rollout is ongoing together with Karo Healthcare.
Builds on previous successes with the first-generation product Kerasal Nail^®/Nalox^®, which was sold for 1.4 billion SEK

Download investor presentations

Significant events during the latest quarter

Moberg Pharma and Karo Healthcare expanded the collaboration and entered April 24th an exclusive license agreement for MOB-015/Terclara® in Australia, New Zealand, South Korea and Taiwan. In all of these new markets, Karo Healthcare is the market leader in antifungal foot treatments with the Lamisil® brand through athlete’s foot products, and the intention is to broaden the portfolio with Moberg Pharma’s nail fungus drug under the same established brand.
On June 8, the collaboration with Karo Healthcare was further expanded to include the commercialization of MOB-015 under the Lamisil® brand in China through the rapidly growing cross-border e-commerce (CBEC) channel.
On June 15, the company announced that the first European countries had approved the transition of MOB-015 to Karo Healthcare's trademark. The approvals enable launch preparations and commercial activities in the first European markets to move forward as planned, with initial deliveries planned around year-end. At the same time, the launch preparations are progressing in Israel, where the first patients are expected to gain access to the product during the third quarter of this year.
The Annual General Meeting on May 21 resolved among other things to implement a long-term incentive program. Lars Johansson, Jack Bradley and Daniel Kaufman were elected as new board members. Lars Johansson was elected as Chairman of the Board of Directors.